Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study

BACKGROUND: Fingolimod was the first oral therapy approved for treating relapsing-remitting multiple sclerosis (RRMS) in 2010. This open-label study evaluated the safety and efficacy of fingolide(R), 0.5 mg in Iranian MS patients during one-year follow-up. METHODS: A multicenter, open-label, longitu...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Caspian J Intern Med
Κύριοι συγγραφείς: Doosti, Rozita, Naser Moghadasi, Abdorreza, Azimi, Amir Reza, Karbalai Saleh, Shahrokh, Etemadifar, Masoud, Shaygannejad, Vahid, Ashtari, Fereshteh, Harirchian, Mohammad Hossein, Siroos, Seyed Bahaadin, Ayramloo, Hormoz, Majdinasab, Nastaran, Hojjati, Seyyed Mohammad Masood, Asghari, Nabiollah, Baghbanian, Seyed Mohammad, Cheraghmakani, Hamed, Abedini, Mahmoud, Sedighi, Behnaz, Mohseni Abbas abadi, Negar, Ghasemitabar, Maedeh, Talebianpour, Sara, Babayi Daylari, Tohid, Dana, Vahid, Ghaleh noie, Neda, Sahraian, Mohammad Ali
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Babol University of Medical Sciences 2021
Θέματα:
Original Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8223042/
https://ncbi.nlm.nih.gov/pubmed/34221275
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.22088/cjim.12.3.263
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια